(NYSE: ZTS) Zoetis's forecast annual revenue growth rate of 5.25% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 36.86%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 24.07%.
Zoetis's revenue in 2026 is $9,467,000,000.On average, 21 Wall Street analysts forecast ZTS's revenue for 2026 to be $4,227,609,005,635, with the lowest ZTS revenue forecast at $4,059,180,049,744, and the highest ZTS revenue forecast at $4,460,623,501,003. On average, 20 Wall Street analysts forecast ZTS's revenue for 2027 to be $4,445,849,031,188, with the lowest ZTS revenue forecast at $4,215,367,302,074, and the highest ZTS revenue forecast at $4,710,945,232,440.
In 2028, ZTS is forecast to generate $4,658,179,268,815 in revenue, with the lowest revenue forecast at $4,327,653,272,668 and the highest revenue forecast at $5,017,832,076,883.